COGT FY2025 SEC EDGAR DEF 14A #45 of 168 in industry

Cogent Biosciences, Inc. CEO pay ratio

The CEO earned $27.8M in FY2025 against median worker pay of $292,285 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-23
Industry
Chemicals & Pharmaceuticals
Industry rank
#45/168

Data updated August 2026

Subscribe to Cogent Biosciences, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
95:1
Moderate (Scale: 0–1000:1)
CEO pay
$27.8M
Median worker
$292,285

Answer first

Cogent Biosciences, Inc.'s FY2025 CEO total of $27.8M ranks #79 of 1,423 complete filings; its 95:1 pay ratio ranks #669. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $292,285. Industry placement uses the FY2025 SIC-28 peer cohort (# 45 of 168, 74th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#79
$27.8M of 1,423 FY2025
Ratio rank
#669
95:1 of 1,423
Industry pct
74th
above the industry median pay ratio

How Cogent Biosciences, Inc. ranks nationally

Cogent Biosciences, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$27,767,075 Top 6% higher than 94% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). Below this entry. $20,000,000–$22,500,000: 24 companies (2%). Below this entry. $22,500,000–$25,000,000: 34 companies (2%). Below this entry. $25,000,000–$27,500,000: 24 companies (2%). Below this entry. $27,500,000–$30,000,000: 16 companies (1%). This entry sits in this band. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Cogent Biosciences, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($27.8M) against pay ratio (95:1) for Cogent Biosciences, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both4408911.510526525.81664414022761754.328879368.539.1:155.1:171:187.0:1102.9:1CEO total payPay ratio (CEO : median worker)Cogent Biosciences, Inc., CEO total pay: 27767075 · Pay ratio (CEO : median worker): 95:1Cogent Biosciences, Inc.Xencor Inc, CEO total pay: 5521205 · Pay ratio (CEO : median worker): 95:1Xencor IncImmunocore Holdings plc, CEO total pay: 10830240 · Pay ratio (CEO : median worker): 92:1Immunocore Holdings plcHexcel Corp /de/, CEO total pay: 7252875 · Pay ratio (CEO : median worker): 98:1Hexcel Corp /de/PERRIGO Co plc, CEO total pay: 9026290 · Pay ratio (CEO : median worker): 91:1PERRIGO Co plcOLIN Corp, CEO total pay: 9798424 · Pay ratio (CEO : median worker): 100:1OLIN Corp
Cogent Biosciences, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Cogent Biosciences, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Cogent Biosciences, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
95:1
FY2025
vs prior FY
+76:1
from FY2024 19:1
CEO $ YoY
+465%
$27.8M latest
Filings shown
2
FY2024–2025
Cogent Biosciences, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $4.9M - $258,662 19:1 -
2025 $27.8M +465% $292,285 95:1 +76:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1622229, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
95:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$27.8M
Companies in Industry
168
vs. Industry Median
Above
#45 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Cogent Biosciences, Inc.: MID · PEAK pay ratio

Cogent Biosciences, Inc.'s FY2025 ratio 95:1 ranks #45 of 168 Chemicals & Pharmaceuticals filers (74th percentile). the CEO earned 95× the median employee ($292,285) in FY2025.

Median employee $292,285 (ELITE-MED); MID · PEAK stamps put about 95 median-wage years per CEO year.

CEO Total Pay

$27.8M

FY2025 Summary Compensation, well above median

Pay Ratio

95:1

Near industry median

Cogent Biosciences, Inc. in the higher Chemicals & Pharmaceuticals third

Cogent Biosciences, Inc.'s FY2025 ratio 95:1 ranks #45 of 168 Chemicals & Pharmaceuticals filers (74th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Cogent Biosciences, Inc.'s $27.8M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #79 and ratio rank #669 split - treat 95:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$27.8M
Median Employee Pay
$292,285
Pay Ratio
95:1
Filing Date
2026-04-23

Company Info

Ticker
COGT
CIK
1622229
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1622229, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Cogent Biosciences, Inc.'s FY2025 ratio 95:1 ranks #45 of 168 Chemicals & Pharmaceuticals filers (74th percentile).

Read with Cogent Biosciences, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · PEAK · ELITE-MED.

Hilton Worldwide Holdings Inc. · PEAK

ABS(ceo_total_comp) peer at $27.7M (Δ $75K lighter vs Cogent Biosciences, Inc.); EXTREME · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Pfizer Inc · PEAK

ABS(ceo_total_comp) peer at $27.6M (Δ $182K lighter vs Cogent Biosciences, Inc.); STEEP · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
Mueller Industries Inc · PEAK

ABS(ceo_total_comp) peer at $27.5M (Δ $223K lighter vs Cogent Biosciences, Inc.); EXTREME · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Lincoln National Corp · PEAK

ABS(ceo_total_comp) peer at $28.0M (Δ $224K heavier vs Cogent Biosciences, Inc.); STEEP · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
Xencor Inc (SIC 28 pole)

Xencor Inc stamps MID · MID$ nearest in-SIC by ABS(pay_ratio) to Cogent Biosciences, Inc.'s MID filing.
National dual ranks · #79/#669

Cogent Biosciences, Inc.'s FY2025 package sits #79 by CEO dollars and #669 by ratio under PEAK · MID.
Comp structure · PEAK

Cogent Biosciences, Inc.'s PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Cogent Biosciences, Inc. (CIK 1622229), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.